FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi
1. FDA recommends earlier MRI monitoring for patients using Biogen's Leqembi. 2. This guidance could influence therapy adoption rates and patient management.
FAQ
Why Neutral?
While increased monitoring raises caution, it may not deter overall Leqembi adoption.
How important is it?
The FDA's recommendation directly concerns Leqembi's usage, impacting its market perception and adoption rate.
Why Short Term?
Monitoring changes might cause immediate adjustments in treatment practices but won't affect Leqembi's long-term acceptance.